José Valentín
García Gutiérrez
Profesor/a Asociado/a en CC. de la Salud
Hospital Regional Universitario de Málaga
Málaga, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Regional Universitario de Málaga (14)
2024
-
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
Frontiers in Oncology, Vol. 14
2023
-
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580
-
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
Cancers, Vol. 15, Núm. 4
-
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE
British Journal of Haematology, Vol. 202, Núm. 5, pp. 942-952
2022
-
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270
-
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group
American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42
2021
2020
-
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
Leukemia and Lymphoma, Vol. 61, Núm. 3, pp. 650-659
-
Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model
Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 12, pp. 2237-2244
2019
-
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients
Annals of Hematology, Vol. 98, Núm. 2, pp. 321-330
2017
-
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia
PLoS ONE, Vol. 12, Núm. 3
-
Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response
Annals of Hematology, Vol. 96, Núm. 1, pp. 81-85
2016
-
Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting
Medicina Clinica, Vol. 146, Núm. 12, pp. 561.e1-561.e8
2015
-
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program
American Journal of Hematology, Vol. 90, Núm. 5, pp. 429-433